AceLink Therapeutics has unveiled promising interim results from its Phase 2 clinical trial evaluating AL01211, a novel oral substrate reduction therapy (SRT), in treatment-naïve male patients with classic Fabry disease. The findings were presented at the 2025 WORLD Symposium in San Diego, California.
Efficacy and Safety Profile
The interim data demonstrates that AL01211, administered as a once-daily oral treatment, achieved significant reductions in GL3 substrate levels. At the 30mg daily dose, patients experienced a 50% reduction in GL3 levels, while the 60mg dose showed even more pronounced and rapid decreases. The drug has maintained a favorable safety profile, with investigators reporting general tolerability among classic male Fabry patients.
Clinical Benefits and Disease Stabilization
Preliminary clinical observations indicate that AL01211 effectively stabilizes key disease markers. Patients showed stabilization of estimated glomerular filtration rate (eGFR) and proteinuria levels, crucial indicators of kidney function in Fabry disease. Additionally, researchers noted encouraging trends in pain reduction and improved quality of life metrics.
Dr. Yan Ouyang, representing the research team led by Professor Nan Chen at Ruijing Hospital, emphasized the treatment's potential: "The interim results from AL01211 treatment are showing promising safety and efficacy trends, underscoring its potential to address critical gaps in Fabry disease treatment."
Trial Design and Progress
The Phase 2 open-label study has successfully completed enrollment, with 18 patients recruited across six clinical sites in China as of December 2024. The trial specifically targets treatment-naïve males with classic Fabry disease, evaluating AL01211's safety, pharmacokinetics, pharmacodynamics, and therapeutic effects. Final topline data is anticipated in Q3 2025.
Therapeutic Innovation
AL01211 represents a significant advancement in Fabry disease treatment as a non-brain-penetrant GCS inhibitor. The drug's high potency, demonstrated by its single-digit nanomolar IC50, combined with once-daily oral administration, offers a potentially transformative alternative to traditional enzyme replacement therapy (ERT), which requires regular intravenous infusions.
Michael Babcock, Head of Research and Development at AceLink Therapeutics, highlighted the company's broader vision: "With a robust pipeline and a commitment to advancing next-generation Substrate Reduction Therapies, AceLink Therapeutics is dedicated to transforming the treatment landscape for patients with Fabry disease and other glycosphingolipid-related disorders."
Drug Mechanism and Development
AL01211 functions by inhibiting glucosylceramide synthase (GCS), the enzyme responsible for initiating glycosphingolipid synthesis. This mechanism of action directly addresses the underlying pathology of Fabry disease, where glycosphingolipid accumulation leads to progressive organ damage. The drug's selective inhibition profile and favorable pharmacological properties support its development as a next-generation oral therapy for glycosphingolipid disorders.
